Trial site
Fukuoka
- 29running trials
- 21closed trials
The trials here
What the 50 trials at this site are about, from their registry records.
- Conditions
- Childhood cancers7 trials
- Chronic myeloid leukaemia6 trials
- Prostate cancer5 trials
- Diffuse large B-cell lymphoma4 trials
- Lung cancer3 trials
- Acute lymphoblastic leukaemia2 trials
- Atopic dermatitis (eczema)2 trials
- Chronic spontaneous urticaria2 trials
- Follicular lymphoma2 trials
- High blood pressure2 trials
- Lupus (SLE)2 trials
- Multiple sclerosis2 trials
- and 24 more
- Phase
- Phase 321 trials
- Phase 210 trials
- Phase 12 trials
- Phase 1/22 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Active, not recruiting18 trials
- Completed18 trials
- Recruiting11 trials
- Terminated3 trials
- Lead sponsor
- Novartis Pharmaceuticals50 trials
Running trials
Recruiting
Recruiting
Recruiting
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Recruiting
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Recruiting
Active, not recruiting
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Active, not recruiting
Recruiting
Active, not recruiting
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Prostate cancer4 recruiting
- Childhood cancers3 recruiting
- Acute lymphoblastic leukaemia1 recruiting
- Atopic dermatitis (eczema)1 recruiting
- Chronic myeloid leukaemia1 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- IgA nephropathy1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Spinal muscular atrophy1 recruiting
Closed trials
Completed
Completed
Completed
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed
Completed
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
Completed
Completed
Completed
Completed
Completed
Completed
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Completed
Completed
Terminated
Completed
Terminated
Completed
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Completed
Terminated
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Completed
Completed
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Site data: ClinicalTrials.govUpdated 18 Nov 2026